Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramipexole Withdrawal in RLS
NCT00152958Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2004
- Primary completion
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in restless legs syndrome (RLS) comparing Pramipexole Maintenance with Placebo Withdrawal (2 arms). Primary endpoint: Time to target event (CGI-I rating in association with RLSRS score above 15) at 3 months. Started Jan 2004; status: completed.
02
Drugs
pramipexole
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT00152958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00152958.